GSK2798745

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

CoughHealthy VolunteersHeart FailureMacular Edema

Phase 1

A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough

TerminatedNCT03372603

GlaxoSmithKlineCough

Start: 2018-04-05End: 2018-10-08Updated: 2019-10-02

Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model

TerminatedNCT03511105

GlaxoSmithKlineHealthy Volunteers

Start: 2018-06-25End: 2018-12-18Updated: 2021-03-29

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

TerminatedNCT04292912

GlaxoSmithKlineMacular Edema

Start: 2020-09-07End: 2022-04-11Updated: 2024-11-08

Phase 2

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

CompletedNCT02497937

GlaxoSmithKlineHeart Failure

Start: 2016-04-13End: 2017-08-21Updated: 2018-09-05

Related Papers

Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge.

2020-10-0115 citations

P115 A segmental LPS challenge study to investigate the pharmacodynamics of a TRPV4 antagonist (GSK2798745) in healthy participants

2019-11-121 citations